Trials Open to Enrollment

AIDS Clinical Trials: New Trials Open to Enrollment

http://www.actis.org/actinewl.htmi

The purpose of this Glaxo Wellcome sponsored study is to obtain preliminary evidence of
antiretroviral activity of 1592U89 when administered in combination with other specific NRTI
agents in NRTI experienced patients and to assess the safety and tolerance of multiple oral doses of
1592U89 when administered in combination with specific marketed NRTIs. For more information,
view the Protocol Database record.
D A Phase III, Randomized, Double Blind, Multicenter Study to Evaluate the Safety and
Efficacy of 1592U89 in Patients With AIDS Dementia Complex. FDA 238B. Drug: 1592U89.
The purpose of this Glaxo Wellcome sponsored study is to evaluate the benefit of adding 1592U89
to current antiretroviral therapies for AIDS dementia complex and to assess the safety and
tolerance of the treatment regimens. For more information, view the Protocol Database record.
l Apheresis Procedures to Obtain Plasma or Lymphocytes for In Vitro Studies. NIAID 81
I-164.
The purpose of this National Institute of Allergy & Infectious Diseases study is to improve the
understanding of the role of cellular factors in determining the levels of HIV produced from
infected cells. For more information, view the Protocol Database record.
Q The Use of Bacteriophage phi x174 to Assess the Immune Competence of HIV-Infected
Patients in Vivo. NIAID 96 1-58. Drug: Bacteriophage phi X 174.
The purpose of this National Institute of Allergy & Infectious Diseases study is to assess the safety
of bacteriophage phi X174 immunization in HIV-infected patients at different stages of disease. To
evaluate the ultility of bacteriophage phi X174 as a tool to qualitatively and quantitatively assess
the immune competence of HIV-infected patients at different stages of disease. For more
information, view the Protocol Database record.
D A Phase III Dosing Study of the Safety and Antiretroviral Activity of Hydroxyurea Alone
and in Combination With ddl Compared With ddl Alone in Subjects With HIV Infection.
NIAID ACTG 307. Drugs: Didanosine, Hydroxyurea.
The purpose of this AIDS Clinical Trials Group study is to determine the safety and tolerability of
hydroxyurea at two doses alone and in combination with didanosine (ddl). To compare the short
term antiviral effect of ddl monotherapy versus hydroxyurea plus ddl, as measured by plasma RNA
levels at 8 weeks of therapy. For more information, view the Protocol Database record.
L An Open-Label, Randomized, Three-Arm, Comparative Trial of a Caloric Supplement With
Peptides and Medium-Chain Triglycerides Versus a Caloric Supplement With Whole
Protein and Long-Chain Triglycerides Versus No Caloric Supplement for the Prevention of
Weight Loss in Individuals With AIDS Who Take a Daily Multivitamin and Mineral
Supplement. NIAID CPCRA 038.
The purpose of this Community Programs for Clinical Research on AIDS study is to compare a
caloric supplement containing peptides and medium-chain triglycerides, a caloric supplement
containing whole protein and long-chain triglycerides, and no caloric supplement for the prevention
of weight loss in individuals with AIDS who take a daily multivitamin and mineral supplement. For
more information, view the Protocol Database record.